Coronavirus Update: Moderna's Vaccine Frontrunner Gets Fast-Tracked, Wuhan To Test Millions
Plus China Tighthens Biosafety Standards, Aimmune Pauses Launch
Executive Summary
Moderna gets green light to proceed to Phase II trial of mRNA vaccine, with its eagerly-awaited Phase I results expected shortly.
You may also be interested in...
Finance Watch: Up, Up And Away – Biopharma Stocks Keep Rising
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Can GSK Veteran Moncef Slaoui Get COVID-19 Vaccine Development To Warp Speed?
President Trump's Operation Warp Speed initiative aims to have a COVID-19 vaccine available by the end of the year; Slaoui, who helped get the first cervical cancer vaccine to market and win European approval of the first malaria vaccine while at GlaxoSmithKline, is tasked with coordinating the government's contributions to coronavirus vaccine effort and achieving what would be twin scientific and manufacturing miracles.
Aimmune Expects ‘Robust’ Demand For Peanut Allergy Treatment Palforzia, Though Slow Launch
Aimmune CEO Jayson Dallas talked to Scrip about the company's field team, allergists' and payers' responses to the first food-derived medicine, and why Viaskin Peanut patch is not a competitive threat.